The total median CD34+ cell number collected was 6.1 × 106/kg (IQR, 4.8–8.2) with no significant difference between myeloma patients requiring Plerixafor or not with a success rate within a single apheresis procedure of 75% in the Plerixafor (CD34+ cell number collected was 6.5 × 106/kg (IQR, 4.9–8.8)) and of 74% in the G-CSF Group (CD34+ cell number collected was 5.7 × 106/kg (IQR, 4.8–7.7)) (Table 3). The gene discussed is CSF3; the disease is plasma cell myeloma.